NOS2 and neoplasm: This is particularly relevant in cancer, in which upregulated NO production, due to the induction of the inducible form of nitric oxide synthase (NOS2), is associated with altered tumor gene expression, poor patient outcomes, increased mortality, and resistance to chemotherapy across cancer types1, including triple-negative breast (TNBC)2–12, lung13–15, prostate16,17, brain18, colon19,20, melanoma21–23, and liver24,25.